Skip to main content
. 2014 Mar 18;171(7):1706–1721. doi: 10.1111/bph.12565

Figure 1.

Figure 1

SHP-2 inhibition significantly ameliorates the clinical signs and disease progression of EAE. Active EAE was induced in C57BL/6 mice by flank s.c. immunization with 200 μg of peptide MOG35–55. (A) SHP-2 inhibitor NSC-87877 (2.5 mg kg−1) or vehicle control was administered i.p. daily from day 0 post immunization. Values are shown as the mean ± SEM of eight mice per group. (B) Spinal cord sections harvested from vehicle-or NSC-87877-treated EAE mice on day 25 post immunization were analysed for degree of inflammation by H&E and for demyelination by Ponceau 2R-fast green (original magnification 200×). (C) NSC-87877 (2.5 mg kg−1) or vehicle control was administered i.p. daily from day 13 post immunization. Values are shown as the mean ± SEM of six mice per group. (D) Active EAE was induced in C57BL/6 mice. SHP-2 inhibitor PHPS1 (1 mg kg−1) or vehicle was administered i.p. daily from the day of immunization. Values are shown as the mean ± SEM of five mice per group.